Hepatocellular carcinoma and a variant alkaline phosphatase

Area of Science:

• Biochemistry
• Oncology
• Clinical Chemistry

Background:

• Hepatocellular carcinoma (HCC) diagnosis often relies on imaging and tumor markers like alpha-fetoprotein (AFP).
• Novel biomarkers are needed for improved sensitivity and specificity in HCC detection.
• Alkaline phosphatase (ALP) isoenzymes can be associated with certain cancers, but specific variants for HCC require further characterization.

Purpose of the Study:

• To characterize a unique alkaline phosphatase (ALP) variant found in patients with hepatocellular carcinoma (HCC).
• To evaluate the diagnostic utility of this novel ALP variant as a potential biomarker for HCC.
• To compare the prevalence and independence of this variant with established HCC markers like AFP.

Main Methods:

• Electrophoretic analysis to determine enzyme mobility.
• Biochemical assays to assess pH optimum and heat stability.
• Inhibition studies using phosphate.
• Comparison of prevalence with alpha-fetoprotein (AFP), Regan, and Nagao isoenzymes in HCC patient sera.

Main Results:

• A distinct alkaline phosphatase (ALP) variant was identified in four HCC patients, differing from the placental D-variant in key biochemical properties.
• This variant showed specificity for hepatocellular carcinoma.
• Its prevalence was approximately 30%, independent of AFP levels, Regan, or Nagao isoenzymes, and total serum ALP activity.
• Patients with this enzyme typically presented with massive, grade III differentiated HCC.

Conclusions:

• The identified alkaline phosphatase variant is a specific marker for hepatocellular carcinoma.
• Its detection in serum may serve as a valuable tool for confirming hepatoma diagnosis.
• This novel enzyme offers an independent diagnostic marker, potentially complementing existing biomarkers like AFP.